Group 1 - The core point of the article is that Hite Bio (300683) plans to acquire a 23.08% stake in Beijing Shadong Biotechnology Co., Ltd. for 62.019 million yuan, increasing its ownership to 98.84%, effectively achieving full control [1] - This acquisition is a follow-up to a share purchase agreement signed in 2014 and aims to integrate the innovative drug research and development platform, paving the way for the commercialization of the core drug CPT (recombinant structural human tumor necrosis factor-related apoptosis-inducing ligand) [1] - The share acquisition process has taken over ten years, and this transaction marks the final stage of integration [1] Group 2 - In the past week (February 7 to 13, 2026), Hite Bio's stock price has shown a volatile downward trend, peaking at 36.03 yuan on February 10, with a single-day increase of 3.17%, but subsequently retracing to a closing price of 32.22 yuan on February 13, resulting in a cumulative decline of 3.13% over five days [2] - On February 10, the turnover rate reached 9.89%, with a trading volume of 419 million yuan, indicating active short-term trading; however, on February 12, there was a net outflow of 14.9611 million yuan from main funds, accounting for 9.75% of the total trading volume [2] - The technical analysis indicates increased volatility in the stock price, with the 20-day Bollinger Bands showing a resistance level at 35.12 yuan and a support level at 27.72 yuan [2] Group 3 - Institutional attention on Hite Bio is relatively low, with the latest sentiment being neutral; one institution predicts a net profit of 77 million yuan for 2025, representing a year-on-year increase of 283.33%, and a forecast of 339 million yuan for 2026, reflecting a year-on-year growth of 340.26%, primarily due to expectations regarding the commercialization potential of the innovative drug CPT [3] - Currently, 100% of institutional ratings are neutral, with no clear target price guidance provided [3]